(Q36459140)

English

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

phase II clinical trial

0 references

cholangiocarcinoma

0 references

gallbladder cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Heinz-Josef Lenz

3

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Syma Iqbal

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Cathryn Rankin

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Philip J Gold

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Syed A Ahmad

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Anthony B El-Khoueiry

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Michael J Messino

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Randall F Holcombe

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Charles D Blanke

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

10 May 2011

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

68

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1595-1602

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

Biliary tract cancer: our experience with gemcitabine treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

30 September 2017

[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japane

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

28 June 2018

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

21 September 2018

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

21 September 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

21 September 2018

Risk factors for gallbladder cancer. An international collaborative case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

21 September 2018

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3519425

21 September 2018

Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule-dependent antitumor effect of gemcitabine in in vivo model system

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21556747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-011-1657-1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

release_3a7ajj6urrc6vchkwer5rqy5qi

1 reference

https://api.fatcat.wiki/v0/release/3a7ajj6urrc6vchkwer5rqy5qi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36459140&oldid=2198922736"